WASHINGTON (AP) — The Food and Drug Administration has approved the first drug treatments for a deadly disease that causes severe lung damage.
The agency on Wednesday approved two novel treatments from Boehringer Ingelheim and Roche for idiopathic pulmonary fibrosis. Patients with the disease experience lung damage over time that makes it difficult to breathe properly. Currently the disease is treatment with oxygen therapy, rehabilitation and lung transplants.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.